Corporate Philanthropy - Best Practices at Novartis AG
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BECG063
Case Length : 23 Pages
Period : 2000-06
Organization : Novartis AG, Novartis Foundation for Sustainable
Pub Date : 2006
Teaching Note : Available
Countries : Switzerland
Industry : Pharmaceutical
To download Corporate Philanthropy - Best Practices at Novartis AG case study (Case Code:
BECG063) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs. 500 ;
For delivery through courier (within India): Rs. 500 + Rs. 25 for Shipping & Handling Charges
» Business Ethics Case Studies
» Case Studies Collection
» ICMR Home
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
|
<< Previous
Excerpts
Background Note
Novartis was the result of a merger between Ciba-Geigy and Sandoz in 1996. The origins of Geigy could be traced back to 1758, when Johann Rudolf Geigy-Gemuseus started a company that traded in materials, chemicals, dyes, and drugs in Basel, Switzerland...
About Novartis Foundation
|
The origin of the Novartis Foundation can be traced back to the year 1979. At
that time, it was known as the Ciba-Geigy Foundation for Cooperation with
Developing Countries (Ciba-Geigy Foundation). The Foundation was formed to help
Third World countries fight against health and poverty related problems. It was
particularly active in the areas of leprosy and TB. After the formation of
Novartis, the Foundation was renamed as the Novartis Foundation for Sustainable
Development. The Novartis Foundation acted as a link between the company and the
community. It communicated the happenings in the external world to the
management of Novartis.
|
|
Novartis Corporate Citizenship Initiative
The UN secretary general, Kofi Annan, proposed the Global Compact in an
address to the World Economic Forum in 1999. The Global Compact had nine
principles drawn from the Universal Declaration of Human Rights 1948 , the
International Labour Office (ILO) Declaration on Fundamental Principles of
Rights at Work, 1988 , and the Rio Principles on Environment and
Development, 1992...
|
|
Tackling Leprosy
The WHO had recommended Multidrug Therapy (MDT) to treat leprosy . Two
of the drugs used in MDT, clofazimine and rifampicin were developed by
Novartis. Since the year 1995, Novartis had been providing MDT for
leprosy patients and was one of the two suppliers providing leprosy
drugs to the WHO. From 1998, MDT was sourced exclusively from Novartis.
In 1999, the Global Alliance for Elimination of Leprosy was formed at
the initiative of the WHO. The members in the alliance were the WHO,
leprosy endemic countries , the International Federation of Anti Leprosy
Associations, the Nippon/Sasakawa Memorial Health Foundation, and
Novartis... |
Fighting Against Tuberculosis
According to WHO estimates, as of 2004, TB killed around two million people every year across the world. Around eight million people developed TB every year. In 1993, the WHO declared TB as a global emergency...
Excerpts Contd...>>
|
|
